Literature DB >> 21286376

Isolation of Fully Human Antagonistic RON Antibodies Showing Efficient Block of Downstream Signaling and Cell Migration.

Zeynep Gunes1, Adriana Zucconi, Mario Cioce, Annalisa Meola, Monica Pezzanera, Stefano Acali, Immacolata Zampaglione, Valeria De Pratti, Luca Bova, Fabio Talamo, Anna Demartis, Paolo Monaci, Nicola La Monica, Gennaro Ciliberto, Alessandra Vitelli.   

Abstract

RON belongs to the c-MET family of receptor tyrosine kinases. As its well-known family member MET, RON and its ligand macrophage-stimulating protein have been implicated in the progression and metastasis of tumors and have been shown to be overexpressed in cancer. We generated and tested a large number of human monoclonal antibodies (mAbs) against human RON. Our screening yielded three high-affinity antibodies that efficiently block ligand-dependent intracellular AKT and MAPK signaling. This effect correlates with the strong reduction of ligand-activated migration of T47D breast cancer cell line. By cross-competition experiments, we showed that the antagonistic antibodies fall into three distinct epitope regions of the RON extracellular Sema domain. Notably, no inhibition of tumor growth was observed in different epithelial tumor xenografts in nude mice with any of the antibodies. These results suggest that distinct properties beside ligand antagonism are required for anti-RON mAbs to exert antitumor effects in vivo.

Entities:  

Year:  2011        PMID: 21286376      PMCID: PMC3026407          DOI: 10.1593/tlo.10211

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  43 in total

1.  Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais.

Authors:  Yi-Qing Chen; Yong-Qing Zhou; Lu-Hong Fu; Dong Wang; Ming-Hai Wang
Journal:  Carcinogenesis       Date:  2002-11       Impact factor: 4.944

2.  Mutation of Cys672 allows recombinant expression of activatible macrophage-stimulating protein.

Authors:  R C Wahl; V J Costigan; J P Batac; K Chen; L Cam; P L Courchesne; S D Patterson; K Zhang; R E Pacifici
Journal:  J Biol Chem       Date:  1997-06-13       Impact factor: 5.157

Review 3.  The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression.

Authors:  Kelsi L Kretschmann; Henok Eyob; Saundra S Buys; Alana L Welm
Journal:  Curr Drug Targets       Date:  2010-09       Impact factor: 3.465

Review 4.  RON, a tyrosine kinase receptor involved in tumor progression and metastasis.

Authors:  E Ramsay Camp; Wenbiao Liu; Fan Fan; Anthony Yang; Ray Somcio; Lee M Ellis
Journal:  Ann Surg Oncol       Date:  2005-03-15       Impact factor: 5.344

Review 5.  Cross-talk between RON receptor tyrosine kinase and other transmembrane receptors.

Authors:  A Danilkovitch-Miagkova; E J Leonard
Journal:  Histol Histopathol       Date:  2001-04       Impact factor: 2.303

6.  The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation.

Authors:  Debora Angeloni; Alla Danilkovitch-Miagkova; Alexei Miagkov; Edward J Leonard; Michael I Lerman
Journal:  J Biol Chem       Date:  2003-11-03       Impact factor: 5.157

7.  The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness.

Authors:  Piera Maggiora; Annalisa Lorenzato; Stefano Fracchioli; Barbara Costa; Massimo Castagnaro; Riccardo Arisio; Dionyssios Katsaros; Marco Massobrio; Paolo M Comoglio; Maria Flavia Di Renzo
Journal:  Exp Cell Res       Date:  2003-08-15       Impact factor: 3.905

8.  RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.

Authors:  Xiang-Ming Xu; Da Wang; Qi Shen; Yi-Qing Chen; Ming-Hai Wang
Journal:  Oncogene       Date:  2004-11-04       Impact factor: 9.867

9.  RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity.

Authors:  Sunny Guin; Hang-Ping Yao; Ming-Hai Wang
Journal:  Mol Pharm       Date:  2010-04-05       Impact factor: 4.939

10.  RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP.

Authors:  G Gaudino; A Follenzi; L Naldini; C Collesi; M Santoro; K A Gallo; P J Godowski; P M Comoglio
Journal:  EMBO J       Date:  1994-08-01       Impact factor: 11.598

View more
  6 in total

Review 1.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

Review 2.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

3.  Recepteur d'Origine nantais (RON) tyrosine kinase splicing variants lacking exons 18 and 19 occur ubiquitously in lung cancer.

Authors:  Soundararajan Krishnaswamy; Abdul Khader Mohammed; Osama E Amer; Gyanendra Tripathi; Majed S Alokail; Nasser M Al-Daghri
Journal:  Int J Clin Exp Med       Date:  2015-11-15

4.  Vitamin D3-dependent VDR signaling delays ron-mediated breast tumorigenesis through suppression of β-catenin activity.

Authors:  Abby L Johnson; Glendon M Zinser; Susan E Waltz
Journal:  Oncotarget       Date:  2015-06-30

5.  Characterizing the Hot Spots Involved in RON-MSPβ Complex Formation Using In Silico Alanine Scanning Mutagenesis and Molecular Dynamics Simulation.

Authors:  Omid Zarei; Maryam Hamzeh-Mivehroud; Silvia Benvenuti; Fulya Ustun-Alkan; Siavoush Dastmalchi
Journal:  Adv Pharm Bull       Date:  2017-04-13

Review 6.  Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials.

Authors:  Hang-Ping Yao; Sreedhar Reddy Suthe; Xiang-Min Tong; Ming-Hai Wang
Journal:  Ther Adv Med Oncol       Date:  2020-05-12       Impact factor: 8.168

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.